KLDO — Kaleido Biosciences Share Price
Last trade - 00:00- $0.00m
- -$16.78m
- $1.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -428.58% | ||
| Return on Equity | -580.57% | ||
| Operating Margin | -7940.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.97 | 1.1 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on microbiome organs to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. It is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development for the prevention of infections caused by multi-drug resistant (MDR) bacteria. The nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
Directors
- Theo Melas-Kyriazi CHM (61)
- Daniel Menichella PRE (61)
- William Duke CFO (48)
- Jerald Korn COO (42)
- Johan Van Hylckama Vlieg CSO (52)
- Geoffrey von Maltzahn DRC (40)
- Bonnie Bassler IND (59)
- Grady Burnett IND (48)
- Jean Mixer IND (54)
- Anne Prener IND (63)
- Anthony Quinn IND (59)
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- January 27th, 2015
- Public Since
- February 28th, 2019
- No. of Shareholders
- 67
- No. of Employees
- 76
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 42,622,559
- Address
- 18 Crosby Dr, BEDFORD, 01730-1402
- Web
- https://kaleido.com/
- Phone
- +1 6176749000
- Auditors
- Deloitte & Touche LLP
Upcoming Events for KLDO
Similar to KLDO
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 21:34 UTC, shares in Kaleido Biosciences are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Kaleido Biosciences last closed at $0.00 and the price had moved by +9900% over the past 365 days. In terms of relative price strength the Kaleido Biosciences share price has outperformed the S&P500 Index by +8292.63% over the past year.
The overall consensus recommendation for Kaleido Biosciences is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Kaleido Biosciences does not currently pay a dividend.
Kaleido Biosciences does not currently pay a dividend.
Kaleido Biosciences does not currently pay a dividend.
To buy shares in Kaleido Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Kaleido Biosciences had a market capitalisation of $0.00m.
Here are the trading details for Kaleido Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: KLDO
Based on an overall assessment of its quality, value and momentum Kaleido Biosciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kaleido Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +8955.66%.
As of the last closing price of $0.00, shares in Kaleido Biosciences were trading -6.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kaleido Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kaleido Biosciences' management team is headed by:
- Theo Melas-Kyriazi - CHM
- Daniel Menichella - PRE
- William Duke - CFO
- Jerald Korn - COO
- Johan Van Hylckama Vlieg - CSO
- Geoffrey von Maltzahn - DRC
- Bonnie Bassler - IND
- Grady Burnett - IND
- Jean Mixer - IND
- Anne Prener - IND
- Anthony Quinn - IND